NovoCure (NVCR) Net Cash Flow (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 97.54% |
| Dec 31, 2025 | -225.27% |
| Sep 30, 2025 | 758.08% |
| Jun 30, 2025 | 160.82% |
| Mar 31, 2025 | -60.55% |
| Dec 31, 2024 | -211.17% |
| Sep 30, 2024 | 107.16% |
| Jun 30, 2024 | -234.44% |
| Mar 31, 2024 | 150.26% |
| Dec 31, 2023 | 9,800.79% |
| Sep 30, 2023 | 96.96% |
| Jun 30, 2023 | -141.17% |
| Mar 31, 2023 | 155.13% |
| Dec 31, 2022 | -3.83% |
| Sep 30, 2022 | -170.14% |
| Jun 30, 2022 | 1,081.59% |
| Mar 31, 2022 | 96.27% |
| Dec 31, 2021 | -245.71% |
| Sep 30, 2021 | 853.80% |
| Jun 30, 2021 | -56.68% |
| Mar 31, 2021 | 646.99% |
| Dec 31, 2020 | -71.62% |
| Sep 30, 2020 | 155.19% |
| Jun 30, 2020 | 341.19% |
| Mar 31, 2020 | 110.73% |
| Dec 31, 2019 | -210.66% |
| Sep 30, 2019 | 0.81% |
| Jun 30, 2019 | 139.80% |
| Mar 31, 2019 | -33.68% |
| Dec 31, 2018 | 106.09% |
| Sep 30, 2018 | 199.16% |
| Jun 30, 2018 | -91.36% |
| Mar 31, 2018 | 1,039.77% |
| Dec 31, 2017 | -240.15% |
| Sep 30, 2017 | 157.06% |
| Jun 30, 2017 | 68.46% |
| Mar 31, 2017 | 11.84% |
| Dec 31, 2016 | -145.24% |
| Sep 30, 2016 | 199.50% |
| Jun 30, 2016 | -905.93% |
| Mar 31, 2016 | -138.37% |
| Dec 31, 2015 | 138.44% |
| Sep 30, 2015 | -88.18% |
| Jun 30, 2015 | 94.46% |
| Mar 31, 2015 | 174.25% |